Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PSMD7 divergent transcript (PSMD7-DT) is classified as a non-coding RNA gene and does not encode a protein product[3][5]. It is annotated in gene databases (GeneCards, BioGPS) as an RNA gene, with no well-characterized protein product, biological function, molecular pathway, or relevance to human disease described in the literature. It should not be confused with PSMD7 (proteasome 26S subunit non-ATPase 7), which is an important proteasome regulatory component implicated in cancer biology and is sometimes a focus for therapeutic research, but PSMD7-DT itself is not[3][1][5]. If a protein-coding target was intended, refer instead to "proteasome 26S subunit non-ATPase 7 (PSMD7)", which is a proteasome subunit involved in protein degradation and cancer cell biology[1][2][4]. The divergent transcript (PSMD7-DT) should be treated as a distinct, non-coding RNA, with currently no validated functional, therapeutic, or diagnostic role.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PSMD7 divergent transcript (PSMD7-DT).